PT - JOURNAL ARTICLE AU - Christine Mona AU - Matthias Benz AU - Firas Hikmat AU - Tristan Grogan AU - Katharina Lueckerath AU - Ali Aria Razmaria AU - Rana Riahi AU - Roger Slavik AU - Mark Grigis AU - Giuseppe Carlucci AU - Kimberly Kelly AU - Johannes Czernin AU - David Dawson AU - Jeremie Calais TI - Validation of FAPi PET biodistribution by immunohistochemistry in patients with solid cancers: a prospective exploratory imaging study DP - 2021 May 01 TA - Journal of Nuclear Medicine PG - 1000--1000 VI - 62 IP - supplement 1 4099 - http://jnm.snmjournals.org/content/62/supplement_1/1000.short 4100 - http://jnm.snmjournals.org/content/62/supplement_1/1000.full SO - J Nucl Med2021 May 01; 62 AB - 1000Introduction: Fibroblast activation protein (FAP)-expressing cancer associated fibroblasts (CAFs), a major component of tumor stroma, confer treatment resistance, promote local progression, metastasis and immunosuppression. Because FAP is selectively expressed in the tumor stroma of many cancers, radiolabeled small molecule ligands targeting FAP are being explored for their use as pan-cancer theranostic agents. The objective was to define the incidence and degree of FAP expression by immunohistochemistry (IHC) across various cancers using Tissue Microarrays (TMAs) and to explore whether gallium-68 FAPi-46 PET image biodistribution faithfully reflects tumor FAP expression from resected tumor and non-tumor specimens. Methods: This study was a prospective, exploratory, open-label, single-center imaging trial in cancer patients conducted in 2020. Referred volunteer patients scheduled to undergo surgical resection of the primary tumor and/or metastases were eligible. Patients underwent one whole body 68Ga-FAPI-46 PET/CT scan. Subsequently, patients underwent surgical resection of the primary tumor and/or metastasis. The Outcome Measure was the Correlation of 68Ga-FAPI-46 PET maximum standardized uptake value (SUVmax) with FAP IHC score in cancer and non-cancer tissue. Trial Registration: ClinicalTrials.gov Identifier: NCT04147494. Results: The incidence of FAP expression in TMAs from 14 cancers ranged from 25 to 100% (mean 76.6± 25.3). 15 patients with the following cancer types were included: colorectal (n=4), head and neck (n=3), pancreas (n=2), breast (n=2), stomach (n=1), esophagus (n=2) and uterus (n=1). All 15 patients subsequently underwent surgery after the scan with a mean time interval of16.1 ± 14.4 days (range 1 - 50 days). Tumor resection was not attempted in 2 patients because unresectable. FAPI SUVmax and IHC score were higher in cancer tissue than in normal tissue: mean FAPI SUVmax 7.4±4.6 (range 1.5-15.9) vs 1.6±1.2 (range 0.4-5.1), (p<0.001) and mean FAP IHC score 2.38±0.65 vs 0.54±0.66 (p<0.001), respectively. The FAP IHC score was positively correlated with FAPI SUVmax (pairwise p=0.001, repeated measures correlations r=0.85 (95% CI 0.53-0.95), p<0.001). Conclusions: The 68Ga-FAPi-46 PET biodistribution across multiple cancers reflects FAP expression as determined by IHC. This translational validation paves the way for large scale prospective trials on the use of 68Ga-FAPi-46 PET/CT as a biomarker and stratification tool for FAP-targeted therapies.